COMPASS Pathways

COMPASS Pathways

COMPASS Pathways is a life sciences company founded in 2016, based in London, UK, that develops clinical research programs and treatments for depression and works to accelerate patient access to evidence-based innovations in mental health.

COMPASS Pathways received Breakthrough Therapy designation in Autumn 2018 from the US Food and Drug Administration (FDA) for its psilocybin therapy to treat depression. COMPASS Pathways will run a large-scale psilocybin therapy clinical trial for treatment-resistant depression in Europe and North America in 2018-2019.

Psilocybin therapy uses psilocybin, the psychoactive ingredient in the psilocybin mushrooms, also known as “magic mushrooms”, and is given along with psychological support. In the UK and the US, Psilocybin therapy how shown promise in terms of efficacy and safety for depression treatment in academic studies.

COMPASS Pathways is making psilocybin available free of charge through the Medicines Chest programme to the European College of Neuropsychopharmacology (ECNP).

Timeline

April 27, 2020

COMPASS Pathways raises a $80,000,000 series B round from Camden Partners, Founders Fund, Able Partners NYC, Perceptive Advisors, ATAI Life Sciences and Skyviews Life Sciences.

October 3, 2018

COMPASS Pathways raises a $32,500,000 series A round.

August 17, 2017

COMPASS Pathways raises a $3,870,000 seed round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Ekaterina Malievskaia

Co-Founder, Chief Medical Officer

George Goldsmith

Co-Founder, Chairman

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Jonah Engel Bromwich
February 28, 2020
www.nytimes.com
Venture capital arrives for psychedelics.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.